Product
Patsnap Eureka
For R&D, Patsnap Eureka makes reading and utilizing patents & technical documents easy.
Patsnap Eureka AIR
Designed for self-driven R&D workflows. Generate viable solutions, solve complex R&D challenges, empower your innovation with AI.
Patsnap Eureka Materials
Designed for material experts only. Revolutionize your material R&D, from search, analyze, to developing new materials.
Feature
TechResearch
Generate reliable direction feasibility study reports for your R&D in just a few steps.
TechSeek
Discover and master advanced knowledge NOW. Basics, ideas, possibilities, all at once.
TechMind
As an expert in R&D Theories, TechMind can generates customized viable solutions instantly.
TechRisk
Analyze your overall solution with one click, know your potential R&D risks in advance.
TechMonitor
Get weekly tech updates, stay abreast of the latest tech innovations and key insights.
Patents
Literature
Hiro is an intelligent assistant for R&D personnel, combined with Patent DNA, to facilitate innovative research.
263results about "Vasoactive intestinal peptide" patented technology
Efficacy Topic
Property
Owner
Technical Advancement
Application Domain
Technology Topic
Technology Field Word
Patent Country/Region
Patent Type
Patent Status
Application Year
Inventor
Peptide agonists of GLP-1 activity
InactiveUS6528486B1Lower blood sugar levelsEffective and stablePeptide/protein ingredientsMetabolism disorderD-GlucoseGlycemic
The present invention relates to novel peptide conjugates which have increased stability and are useful in the treatment of excess levels of blood glucose.
Owner:ZP HLDG SPV
Use of exendins for the reduction of food intake
InactiveUS6956026B2Reduce appetiteReduce cardiac riskPeptide/protein ingredientsPharmaceutical delivery mechanismFeeding disabilityCvd risk
Methods for treating conditions or disorders which can be alleviated by reducing food intake are disclosed which comprise administration of an effective amount of an exendin or an exendin agonist, alone or in conjunction with other compounds or compositions that affect satiety. The methods are useful for treating conditions or disorders, including obesity, Type II diabetes, eating disorders, and insulin-resistance syndrome. The methods are also useful for lowering the plasma glucose level, lowering the plasma lipid level, reducing the cardiac risk, reducing the appetite, and reducing the weight of subjects. Pharmaceutical compositions for use in the methods of the invention are also disclosed.
Owner:ASTRAZENECA PHARMA LP
Long lasting synthetic glucagon-like peptide {GLP-1}
Modified insulinotropic peptides are disclosed. The modified insulinotropic peptides are capable of forming a peptidase stabilized insulinotropic peptide. The modified insulinotropic peptides are capable of forming covalent bonds with one or more blood components to form a conjugate. The conjugates may be formed in vivo or ex vivo. The modified peptides are administered to treat humans with diabetes and other related diseases.
Owner:CONJUCHEM
Methods for glucagon suppression using modified exendins
InactiveUS7153825B2Saccharide peptide ingredientsVasoactive intestinal peptideDiseaseBiological half-life
We claim a method of lowering plasma glucagon in a subject in need thereof comprising administering to the subject a composition comprising a modified exendin or modified exendin analog, wherein said modification comprises one or more molecule linked to an exendin or the exendin analog wherein said molecule is selected from the group consisiting of polyethylene glycol, gelatin and / or albumin. The modified exendin or the modified exendin analog has activity of suppressing glucagon secretion and / or lowering glucagon levels in the subject and possesses increased biological half-life compared to unmodified exendin or unmodified exendin analog. The method is useful in treating hyperglucagonemia and other disorders that would be benefited by lowering plasma glucagon or suppressing glucagon secretion.
Owner:AMYLIN PHARMA INC
Modified therapeutic peptides with extended half-lives in vivo
A method for protecting a peptide from peptidase activity in vivo, the peptide being composed of between 2 and 50 amino acids and having a C-terminus and an N-terminus and a C-terminus amino acid and an N-terminus amino acid is described. In the first step of the method, the peptide is modified by attaching a reactive group to the C-terminus amino acid, to the N-terminus amino acid, or to an amino acid located between the N-terminus and the C-terminus, such that the modified peptide is capable of forming a covalent bond in vivo with a reactive functionality on a blood component. In the next step, a covalent bond is formed between the reactive group and a reactive functionality on a blood component to form a peptide-blood component conjugate, thereby protecting said peptide from peptidase activity. The final step of the method involves the analyzing of the stability of the peptide-blood component conjugate to assess the protection of the peptide from peptidase activity.
Owner:CONJUCHEM
Novel peptide agonists of GLP-1 activity
InactiveUS20040106547A1Lower blood sugar levelsEffective and stablePeptide/protein ingredientsVasoactive intestinal peptideDiseaseGastric emptying
Owner:ZEALAND PHARM AS
Hybrid polypeptides with selectable properties
InactiveUS20060094652A1Reverse glucose intoleranceIncrease beta cell massPeptide/protein ingredientsAntibody mimetics/scaffoldsDyslipidemiaBlood plasma
The present invention relates generally to novel, selectable hybrid polypeptides useful as agents for the treatment and prevention of metabolic diseases and disorders which can be alleviated by control plasma glucose levels, insulin levels, and / or insulin secretion, such as diabetes and diabetes-related conditions. Such conditions and disorders include, but are not limited to, hypertension, dyslipidemia, cardiovascular disease, eating disorders, insulin-resistance, obesity, and diabetes mellitus of any kind, including type 1, type 2, and gestational diabetes.
Owner:AMYLIN PHARMA INC
Composition for long-acting peptide analogs
ActiveUS20090088387A1Increase perfusionImprove the level ofAntibacterial agentsPeptide/protein ingredientsHalf-lifeArginine
The invention describes compositions of peptide analogs that are active in blood or cleavable in blood to release an active peptide. The peptide analogs have a general formula: A-(Cm)x-Peptide, wherein A is hydrophobic moiety or a metal binding moiety, e.g., a chemical group or moiety containing 1) an alkyl group having 6 to 36 carbon units, 2) a nitrilotriacetic acid group, 3) an imidodiacetic acid group, or 4) a moiety of formula (ZyHisw)p, wherein Z is any amino acid residue other than histidine, His is histidine, y is an integer from 0-6; w is an integer from 1-6; and p is an integer from 1-6; wherein if A has alkyl group with 6 to 36 carbon units x is greater than 0; and Cm is a cleavable moiety consisting of glycine or alanine or lysine or arginine or N-Arginine or N-lysine, wherein x is an integer between 0-6 and N may be any amino acid or none. The peptide analogs are complexed with polymeric carrier to provide enhanced half-life.
Owner:PHARMAIN CORP
Biosynthetic polypeptides utilizing non-naturally encoded amino acids
InactiveUS7638299B2Improve stabilityPromote circulationVirus peptidesVasoactive intestinal peptideAmino acidBiosynthesis
Owner:AMBRX
Transepithelial delivery of peptides with incretin hormone activities
InactiveUS20060084604A1Promote insulin secretionSustained releaseNervous disorderPeptide/protein ingredientsDiabetes mellitusIncretin Hormone
Compositions and methods are disclosed for the treatment of diabetes and related diseases using peptides with incretin hormone activity. Preferably, the peptide with incretin hormone activity is GLP-1, exendin or an analog of GLP-1 or exendin. The peptides with incretin hormone activity are administered transepithelially using a transepithelial carrier peptide. The transepithelial peptide contains sufficient amino, guanidine or amidino groups to stimulate transepithelial delivery. In some embodiments, the transepithelial carrier and the peptide with incretin hormone activity are embedded in a pressure sensitive adhesive layer of a plaster or patch.
Owner:NITTO DENKO CORP
Stabilized Exendin-4 compounds
InactiveUS7544657B2Easy to storeImprove consistencyNervous disorderPeptide/protein ingredientsIsomerizationAgonist
Owner:ZEALAND PHARM AS
Glp-1 exendin-4 peptide analogs and uses thereof
Owner:UNITED STATES OF AMERICA
Extendin derivatives
InactiveUS7226990B2Good synergistic effectAdditional therapeutic advantageMetabolism disorderPeptide sourcesPeptideC-Terminal Amino Acid
The present invention relates to novel derivatives of exendin-4 or exendin-4 fragments, wherein the derivatives have a lipophilic substituent attached, optionally via a spacer, to an amino acid residue, which is not the N-terminal or C-terminal amino acid residue of the derivative.
Owner:NOVO NORDISK AS
Transepithelial delivery of peptides with incretin hormone activities
InactiveUS7442682B2Sustained releasePromote secretionNervous disorderPeptide/protein ingredientsDiabetes mellitusDisease
Compositions and methods are disclosed for the treatment of diabetes and related diseases using peptides with incretin hormone activity. Preferably, the peptide with incretin hormone activity is GLP-1, exendin or an analog of GLP-1 or exendin. The peptides with incretin hormone activity are administered transepithelially using a transepithelial carrier peptide. The transepithelial peptide contains sufficient amino, guanidine or amidino groups to stimulate transepithelial delivery. In some embodiments, the transepithelial carrier and the peptide with incretin hormone activity are embedded in a pressure sensitive adhesive layer of a plaster or patch.
Owner:NITTO DENKO CORP
Stabilized exendin-4 compounds
InactiveUS20060194719A1Easy to storeImprove consistencyNervous disorderPeptide/protein ingredientsDiabetes mellitusIsomerization
The present invention disclosed compositions comprising a stabilized Exendin-4 (1-39) and related compounds. The invention describes stabilized Exendin-4 agonists that include at least one modified amino acid residue particularly at positions Gln 13, Met14, Trp25, or Asn28 of the Exendin-4 (1-39) molecule. Disclosed are preferred modifications of deaminated, hydrolyzed, oxidized, or isomerized reaction products of the specified amino acid residues corresponding to the same positions in the Exendin-4 molecule. The invention also relates to methods of making and using the stabilized Exendin compounds, such as for the treatment of diabetes.
Owner:ZEALAND PHARM AS
Exendin analog formulations
InactiveUS20060069029A1Slow gastric emptyingLowering plasma glucose levelPowder deliveryPeptide/protein ingredientsAgonistPharmacology
Owner:ASTRAZENECA PHARMA LP
Exendin or its analogs with polyethylene group and its preparation and application
An Exendin with carbowax group or the analog of Extendin and the preparation of Extendin relates to the technical field of Exendin or the analog of Extendin which is modified with one or more than one carbowax and the preparation of the Extendin. The present invention aims at solving the technical problem that the medicine taking interval is short; the bioactivity is greatly reduced after being modified with carbowax so as to increase the medicament dose, which yet cannot be carried out practically. The Extendin or the analog of Extendin of the present invention which is modified with carbowax is characterized by long hall-life, high activity and low immunogenicity.
Owner:SHANGHAI HUAYI BIO LAB CO LTD
An insulinotropic complex using an immunoglobulin fragment
ActiveUS20100105877A1Improve efficacyProlong lifePeptide/protein ingredientsVasoactive intestinal peptidePeptide drugHalf-life
The present invention relates to an insulinotropic peptide conjugate having improved in-vivo duration of efficacy and stability, comprising an insulinotropic peptide, a non-peptide polymer and an immunoglobulin Fc region, which are covalently linked to each other, and a use of the same. The insulinotropic peptide conjugate of the present invention has the in-vivo activity which is maintained relatively high, and has remarkably increased blood half-life, and thus it can be desirably employed in the development of long acting formulations of various peptide drugs.
Owner:HANMI SCI CO LTD
Novel GLP-1 compounds
InactiveUS20070042956A1Nervous disorderPeptide/protein ingredientsOrganic chemistryMedicinal chemistry
Owner:NOVO NORDISK AS
Modified exendin and exendin agonists
Novel modified exendins and exendin agonists having an exendin or exendin agonist linked to one or more polyethylene glycol polymers, for example, and related formulations and dosages and methods of administration thereof are provided. These modified exendins and exendin agonists, compositions and methods are useful in treating diabetes and conditions that would be benefited by lowering plasma glucose or delaying and / or slowing gastric emptying or inhibiting food intake.
Owner:AMYLIN PHARMA INC
Differentiation of non-insulin producing cells into insulin producing cells by GLP-1 or exendin-4 and uses thereof
InactiveUS7056734B1Peptide/protein ingredientsPancreatic cellsDiabetes mellitusInsulin producing cell
The present invention relates to a population of insulin producing cells made by a process comprising contacting non-insulin producing cells with a growth factor selected from the group consisting of GLP-1 or Exendin-4, growth factors having amino acid sequences substantially homologous to GLP-1 or Exendin-4, and fragmets thereof. The present invention also relates to methods of differentiating non-insulin producing cells into insulin producing cells and of enriching a population of cells for insulin-producing cells. The present invention also relates to methods of treating diabetes.
Owner:THE GENERAL HOSPITAL CORP +1
Peptide agonists of GLP-1 activity
InactiveUS20070111940A1Improve glucose toleranceLower blood sugar levelsPeptide/protein ingredientsVasoactive intestinal peptideGastric emptyingAgonist
Novel peptide agonists of GLP-1 activity useful for lowering blood glucose levels. The novel peptides comprise variants of the GLP-1 or the exendin-4 polypeptide sequence and are pharmacologically active and stable. These peptides are useful in the treatment of diseases that benefit from regulation of excess levels of blood glucose and / or regulation of gastric emptying, such as diabetes and eating disorders.
Owner:LARSEN BJARNE DUE +2
Exendin-4 and analog fusion protein thereof
ActiveCN101891823APromote regenerationPromote repairPeptide/protein ingredientsAntibody mimetics/scaffoldsDiseaseMotility
The invention discloses exendin-4, an analog fusion protein thereof, the corresponding polynucleotide sequence, carrier, host cell and pharmaceutical composite and a preparation method and applications of the fusion protein. The fusion protein is prepared by fusing exendin-4 and analog thereof with human immunoglobulin IgG2-Fc through special connecting peptide and has better stability and loner half-life in vivo. The fusion protein can be administered by performing local delivery, using aerosol and using injection. The fusion protein can promote the regeneration and repair of islet beta cells, increase islet beta cells, promote the secretion of insulin and improve the sensitivity of organism to insulin. The fusion protein is used to cure diabetes, adiposity and other diseases which can be benefited by reducing plasma glucose and inhibiting gastrointestinal motility and gastric emptying.
Owner:BEIJING DONGFANG BIOTECH
GLP-1 exendin-4 peptide analogs and uses thereof
Owner:UNITED STATES OF AMERICA
Peptide compositions with effects on blood glucose
InactiveUS20050222036A1Strengthen associationEnhance spatial learningPeptide/protein ingredientsMetabolism disorderDiseaseMemory retention
The present invention provides compositions and methods for ameliorating neurological or memory disorders and improving learning and cognition through the increase of cyclic AMP. Gilatides, peptides comprising the nine amino acid sequence (SEQ ID NO:1), and functional analogs thereof are disclosed to modulate neurological activity when administered to a subject. The methods of the invention can be used to prevent or treat neurological disorders as well as improve memory retention and acquisition. In addition, the invention can be used to modulate insulin levels and blood glucose. The invention includes pharmaceutical compositions comprising a therapeutically or prophylactically effective amount of a Gilatide peptide or a functional analog thereof.
Owner:THOMAS JEFFERSON UNIV
Differentiation of non-insulin producing cells into insulin producing cells by GLP-1 or exendin-4 and uses thereof
The present invention relates to a population of insulin producing cells made by a process comprising contacting non-insulin producing cells with a growth factor selected from the group consisting of GLP-1 or Exendin-4, growth factors having amino acid sequences substantially homologous to GLP-1 or Exendin-4, and fragments thereof. The present invention also relates to methods of differentiating non-insulin producing cells into insulin producing cells and of enriching a population of cells for insulin-producing cells. The present invention also relates to methods of treating diabetes.
Owner:THE GOVERNMENT OF THE UNITED STATES OF AMERICA AS REPRESENTED BY THE SEC DEPT OF HEALTH & HUMAN SERVICES NAT INST OF HEALTH OFFICE OF TECH TRANSFER +1
Exendin analog formulations
InactiveUS7399489B2Promote formationImprove stabilityPowder deliveryPeptide/protein ingredientsAgonistPharmacology
Owner:ASTRAZENECA PHARMA LP
VPAC1 selective antagonists and their pharmacological methods of use
InactiveUS20050203009A1High activityHigh expressionPeptide/protein ingredientsAntibody mimetics/scaffoldsVpac1 receptorGrowth hormone–releasing hormone
The disclosed invention relates to selective VPAC1 antagonists, related formulations, dosages and methods of use. The selective VPAC1 antagonists of the invention comprise a vasoactive intestinal peptide component and a growth hormone releasing hormone component capable of selectively binding to and antagonizing the VPAC1 receptor at significantly lower concentrations than those concentrations at which it binds to and antagonizes the VPAC2 receptor.
Owner:BAYER PHARMA CORP
High purity peptides
InactiveUS20080287650A1High HPLC purityThymosin peptidesPeptide preparation methodsNesiritideHPLC measurement
Owner:TEVA PHARM USA INC
Novel exendin agonist formulations and methods of administration thereof
InactiveUS20060183677A1Slow gastric emptyingLower levelPowder deliveryPeptide/protein ingredientsGastric emptyingPlasma glucose
Novel exendin and exendin agonist compound formulations and dosages and methods of administration thereof are provided. These compositions and methods are useful in treating diabetes and conditions that would be benefited by lowering plasma glucose or delaying and / or slowing gastric emptying or inhibiting food intake.
Owner:AMYLIN PHARMA INC
Who we serve
- R&D Engineer
- R&D Manager
- IP Professional
Why Patsnap Eureka
- Industry Leading Data Capabilities
- Powerful AI technology
- Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.
© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com